Aerie Pharmaceuticals - AERI Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last twelve months. There are currently 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AERI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AERI, but not buy additional shares or sell existing shares.
View AERI analyst ratings or view top-rated stocks.

6 equities research analysts have issued 12 month price objectives for Aerie Pharmaceuticals' stock. Their AERI share price forecasts range from $14.00 to $25.00. On average, they expect the company's stock price to reach $16.90 in the next twelve months. This suggests a possible upside of 11.8% from the stock's current price.
View analysts price targets for AERI or view top-rated stocks among Wall Street analysts.

Aerie Pharmaceuticals' stock was trading at $7.02 at the start of the year. Since then, AERI stock has increased by 115.2% and is now trading at $15.11.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our AERI earnings forecast.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) posted its quarterly earnings data on Thursday, August, 4th. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.20. The business earned $33.31 million during the quarter, compared to analysts' expectations of $32.47 million. During the same quarter in the previous year, the firm posted ($0.67) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Shares of AERI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AERI stock can currently be purchased for approximately $15.11.

Aerie Pharmaceuticals (NASDAQ:AERI) has a market capitalization of $745.83 million and generates $194.13 million in revenue each year. The company earns $-74,810,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis.

The company employs 376 workers across the globe.

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The official website for the company is www.aeriepharma.com. The company can be reached via phone at (919) 237-5300, via email at abavishi@aeriepharma.com, or via fax at 949-526-8787.